Artiva reports Q1 net loss $20.3M; AlloNK IND cleared for autoimmune basket trial

Artiva Biotherapeutics, Inc.

2025-Q1 EPS reported -$0.83

Cash, cash equivalents and investments of $166.0M as of March 31, 2025; cash runway into Q2 2027.
R&D expenses $17.1M (vs $11.2M YoY); net loss $20.3M (vs $14.0M YoY).
IND cleared for Phase 2a basket trial of AlloNK+rituximab in refractory RA, Sjögren's, myositis, scleroderma; site initiation underway.
Longer-term B-NHL data at ASGCT shows CR rates and median DOR in line with approved auto-CAR-T therapies.
Appointed Subhashis Banerjee, M.D. as CMO on April 8, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.